Axinn Advised Thermo Fisher on $12.5B Acquisition of QIAGEN
March 3, 2020
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its proposed $12.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The Axinn antitrust team included partners John Harkrider, Michael Keeley, and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
IBA Annual Conference 2025
Speaking Engagement
Antitrust
GCR Live: Global Merger Control 2025
Speaking Engagement
Antitrust
Thomson Reuters 24th Annual Law Firm COO & CFO Forum
Speaking Engagement
LegalNEXT 2025
Speaking Engagement
Antitrust
Informa Antitrust Texas 2025
Speaking Engagement
Antitrust
Shifting Trends in Healthcare Antitrust Enforcement: Navigating the Evolving Landscape
Axinn Viewpoints
Antitrust
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
MCCA Gala 2025
Sponsorship
Antitrust
In Fashion, One Day You’re In and the Next Day You’re Out (Of Chances to Plead Violations of the Sherman Act)
Axinn Viewpoints
Antitrust
Axinn Honored at the 2025 Transform Awards North America
Awards & Recognitions